Zydus Lifesciences Limited (ZYDUSLIFE) — Financial Results | 6 November 2025(3 announcements)

Zydus Lifesciences received USFDA Orphan Drug Designation (ODD) for Desidustat, a novel HIF-prolyl hydroxylase inhibitor, for treating beta-thalassemia. The designation provides eligibility for seven-year marketing exclusivity upon USFDA approval, tax credits, and prescription drug user fee exemptions. Desidustat has demonstrated potential to increase hemoglobin and red blood cell counts in preclinical studies, addressing an unmet medical need for patients requiring lifelong blood transfusions.

Zydus Lifesciences Limited disclosed an investor call audio recording discussing unaudited financial results for the quarter and half-year ended September 30, 2025, in compliance with SEBI listing regulations. The recording is available on the company's website, providing shareholders access to management commentary on operational and financial performance during the period.

Zydus Lifesciences reported Q2 FY26 revenues of ₹61,232 million, growing 17% YoY, with net profit rising 38% YoY to ₹12,586 million. EBITDA margin expanded 500 basis points to 32.9%. India formulations sustained growth at 8.4% YoY, US formulations grew 13.5% YoY, and International Markets surged 39.4% YoY. The company acquired UK-based Comfort Click Ltd to expand consumer wellness internationally. Net debt improved to ₹22,787 million from negative ₹48,880 million in March 2025.